Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PrevEp004 (topiramate)
- Development stage
- Preclinical
- Lead developer
- Prevep
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
PrevEp004 is a novel intravenous (IV) formulation of topiramate being developed by Prevep for the treatment of neonatal seizures and status epilepticus. Topiramate is a broad-spectrum anticonvulsant that exerts its therapeutic effects through multiple mechanisms, including the modulation of voltage-gated sodium channels, antagonism of AMPA/kainate-type glutamate receptors, and inhibition of carbonic anhydrase isoenzymes. This IV formulation is specifically designed to address the need for rapid delivery and precise dosing in emergency clinical settings where oral administration is not feasible, such as in neonates or patients experiencing acute status epilepticus. By providing a parenteral route for topiramate, PrevEp004 aims to offer both antiepileptic and neuroprotective benefits in critical care environments.
- Other names
- IV Topiramateintravenous topiramate
02
Targets
AMPAR (AMPA receptor)CA2 (Carbonic Anhydrase 2)CA4 (Carbonic anhydrase 4)GABAA (Gamma-aminobutyric acid receptor)GRIK1 (Glutamate ionotropic receptor kainate type subunit 1)CA (Carbonic anhydrase)Kainate-type ionotropic glutamate receptorNaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on PrevEp004 (topiramate).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PrevEp004 (topiramate).